FILING ANALYSIS · FRIDAY, NOVEMBER 13
PDS Biotechnology Corp PDSB — 8-K: Results of Operations and Financial Condition
negative
The company announced a PIPE financing of up to $22.3 million, which may lead to dilution, and reported a net loss of $7.6 million for the third quarter, with cash and cash equivalents of $15.2 million as of September 30, 2026. The financing and related option agreement with NantWorks may have implications for the company's future development and licensing plans.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →